Follicular Lymphoma | Tumor

Revlimid-Rituxan Combo May Offer Alternative to Chemotherapy for Lymphoma Subtype

August 22nd 2022

The combination treatment demonstrated survival and safety results similar to those of chemotherapy for patients with advanced, untreated follicular lymphoma.

FDA’s Approval of Breyanzi Gives Some Patients With Lymphoma a ‘Life-Saving Therapy', Says Expert

July 8th 2022

The FDA approval of Breyanzi, a novel CAR-T cell therapy, provides many patients with lymphoma a new treatment option that can be used earlier in the course of their disease, according to an expert.

FDA Grants Lunsumio Priority Review for Relapsed/Refractory Follicular Lymphoma

July 7th 2022

The priority review comes following positive clinical trial results, which may lead to a shift in the treatment paradigm for follicular lymphoma, according to an expert.

FDA Approves Kymriah for Relapsed/Refractory Follicular Lymphoma

May 31st 2022

Kymriah, a CAR-T cell therapy, was approved by the Food and Drug Administration for the treatment of patients with pretreated, relapsed/refractory follicular lymphoma.

Experimental Lymphoma Drug Shows ‘Robust Clinical Activity,’ Researchers Say

February 25th 2022

Treatment with TRPH-222 led to lasting responses in certain patients with relapsed/refractory B-cell non-Hodgkin lymphomas, warranting a larger investigation into the drug, according to the researchers.

Kymriah Shows ‘Huge Potential’ for Patients With Heavily Pretreated, Relapsed Follicular Lymphoma

January 24th 2022

Kymriah may represent a more effective option than currently available treatments for patients with heavily pretreated follicular lymphoma, according to an expert from The University of Texas MD Anderson Cancer Center.

Third Full Dose of COVID-19 Vaccine Increases Antibody Response in Patients with Blood Cancers

December 23rd 2021

New findings show that 43% of patients with certain blood cancers produced COVID-19 antibodies after receiving a third full dose of the mRNA vaccine.

FDA Will Review New Drug to Treat Non-Hodgkin Lymphoma

November 1st 2021

The Food and Drug Administration will review parsaclisib for the treatment of patients with follicular lymphoma, marginal zone lymphoma and mantle cell lymphoma.

FDA Speeds Up Review of CAR-T Cell Therapy to Treat Follicular Lymphoma

October 28th 2021

Kymriah was granted a priority review for the treatment of pretreated patients with relapsed or refractory follicular lymphoma.

When the Daughter of a Pediatric Oncologist Receives a Cancer Diagnosis

October 14th 2021

“We tried very hard, my daughter and I, to have a daughter-father relationship, not a daughter-doctor relationship,” said Dr. Michael Weiner on this episode of the “CURE® Talks Cancer” podcast, in which he discussed his career, his own cancer journey and his daughter’s diagnosis.

FDA Approves Yescarta for Third-Line Treatment of Relapsed or Refractory Follicular Lymphoma

March 6th 2021

This accelerated FDA approval is the first CAR T-cell therapy approved for the treatment of patients with indolent follicular lymphoma.

Bringing Clinical Trials in Cancer Closer to Home

February 17th 2021

Local access to national cancer studies allows patients to receive promising new treatments in the most convenient setting possible: Their own community.

FDA Approves Ukoniq in Certain Previously Treated Patients with Marginal Zone and Follicular Lymphoma

February 5th 2021

The Food and Drug Administration has granted an accelerated approval to Ukoniq for the treatment of certain adults with previously treated relapsed or refractory marginal zone lymphoma and relapsed or refractory follicular lymphoma.

The Top 5 News and Updates in Follicular Lymphoma That Patients May Have Missed in 2020

December 30th 2020

A roundup of some of the most read news and updates in follicular lymphoma in 2020 from CURE®.

One-Half Teaspoon

December 26th 2020

Aileen Holthaus writes about her first day of chemotherapy for follicular lymphoma, and the challenges it presented.

Novel Drugs Look Promising in the Treatment of Follicular Lymphoma

November 4th 2020

One recently approved drug and two experimental treatments offer the promise of a wider range of options for patients with follicular lymphoma, according to Dr. Germame Ajebo.

Trading Places: A Father and Daughter's Journey with Lymphoma

October 30th 2020

Bob Meyers and his daughter Leslie Watson have always been close. In fact, they live right down the street from one another in their Georgia neighborhood. So, when Watson received the diagnosis of clear cell carcinoma in the summer of 1996, and then follicular lymphoma later that fall, Meyers was there by her side as her devoted caregiver.

Tazverik a Safe and Effective Option for Heavily Pretreated Patients with Follicular Lymphoma

October 27th 2020

In addition to showing clinically meaningful, durable responses, Tazverik (tazemetostat) was generally well-tolerated in heavily pretreated patients with relapsed or refractory follicular lymphoma, according to the results of an open-label, single-arm, multicenter phase 2 study.

Aliqopa in Combination with Rituxan Meets Primary End Point for Indolent Non-Hodgkin’s Lymphoma

October 16th 2020

A study evaluating the efficacy of Aliqopa (copanlisib) in combination with Rituxan (rituximab) in patients with indolent non-Hodgkin’s lymphoma who have relapsed after at least one prior line of therapy also involving Rituxan has met its primary endpoint, according to Aliqopa’s manufacturer, Bayer.

Follicular Lymphoma Treatment Could Rely on Immunotherapy in Therapy Sequencing

October 15th 2020

Follicular lymphoma treatment options are changing, and according to one expert, immunotherapy could become a major part of therapy sequencing.

Expert Discusses the Need for Safe and Effective Treatments for Aggressive Follicular Lymphoma

October 14th 2020

Dr. Kami J. Maddocks discusses the importance of effective treatments for patients with aggressive follicular lymphoma and the treatment challenges they face.

Consolidative High-Dose Therapy, Autologous Stem Cell Transplant After R-CHOP for Follicular Lymphoma Does Not Improve Survival

October 7th 2020

“Collectively, our mature data provide the most definitive evidence supporting current guidelines, that HDT/ASCT should not be offered to unselected patient(s) (with follicular lymphoma) in the frontline setting,” the authors wrote.

Phase 2 Interim Analysis Shows Improved Response in Patients with Follicular Lymphoma

August 12th 2020

“These results further support our efforts to reimagine medicine in this incurable malignancy and reach this underserved patient population, who are historically burdened with several years of various treatments,” said Dr. John Tsai.

'No Question' Patients with Follicular Lymphoma Can Benefit from FDA's Approval of Tazverik

July 13th 2020

“Having new options is important, particularly when patients have already been through chemotherapy and some of the other therapies that are available,” said Dr. John P. Leonard.

FDA Approves Tazverik for Certain Patients With Relapsed/Refractory Follicular Lymphoma

June 18th 2020

The Food and Drug Administration approved Tazverik for adults with relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation and have received treatment with at least two systemic therapies, as well as patients who have no other treatment options.